Eisai Co Ltd
TSE:4523

Watchlist Manager
Eisai Co Ltd Logo
Eisai Co Ltd
TSE:4523
Watchlist
Price: 4 605 JPY -2.15% Market Closed
Market Cap: 1.3T JPY

Operating Margin
Eisai Co Ltd

7.6%
Current
6%
Average
6.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
7.6%
=
Operating Profit
61B
/
Revenue
804.4B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
JP
Eisai Co Ltd
TSE:4523
1.3T JPY
8%
US
Eli Lilly and Co
NYSE:LLY
954.7B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
505.3B USD
27%
CH
Roche Holding AG
SIX:ROG
253.1B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP
24%
CH
Novartis AG
SIX:NOVN
203.4B CHF
33%
US
Merck & Co Inc
NYSE:MRK
246.3B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
202.5B USD
11%
US
Pfizer Inc
NYSE:PFE
146.7B USD
29%
No Stocks Found

Eisai Co Ltd
Glance View

Market Cap
1.3T JPY
Industry
Pharmaceuticals

Eisai Co., Ltd., established in 1941, has emerged as a formidable player in the global pharmaceutical landscape, forging its reputation through a steadfast commitment to "human health care" (hhc). Rooted in Tokyo, the company orbits around the development of innovative treatments targeting neurology and oncology, positioning itself as a beacon of hope for patients worldwide. Eisai's journey is characterized by a persistent focus on medicinal breakthroughs in areas such as Alzheimer’s disease, liver cancer, and epilepsy—disease states that critically affect the quality of life but often have limited treatment options. Through its rigorous research and development efforts, the company crafts both small molecule drugs and biologics, distinguishing itself with flagship products like Aricept for Alzheimer's and Lenvima for cancer, both of which have cemented its reputation in the medical community and are vital streams of revenue. Eisai's business framework is intricately woven into a global tapestry of partnerships and collaborations, which amplifies its market reach and bolsters its financial performance. By strategically aligning with global pharmaceutical giants and leveraging robust patent portfolios, Eisai extends its innovative therapies to numerous markets. This strategic network allows it to not only enhance drug distribution and sales but also to engage in co-development, introducing shared stewardship in groundbreaking research. The company's financial structure is further reinforced through a diversified portfolio, inclusive of both branded prescription drugs and over-the-counter products, thus facilitating consistent cash flow and enabling ongoing investments in research. These deliberate steps underscore Eisai's pursuit of longevity in a fiercely competitive industry, ensuring it remains well-poised to continually adapt and thrive amidst evolving healthcare challenges.

Eisai Co Ltd Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
7.6%
=
Operating Profit
61B
/
Revenue
804.4B
What is the Operating Margin of Eisai Co Ltd?

Based on Eisai Co Ltd's most recent financial statements, the company has Operating Margin of 7.6%.

Back to Top